<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Caredx Inc — News on 6ix</title>
<link>https://6ix.com/company/caredx-inc</link>
<description>Latest news and press releases for Caredx Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/caredx-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683553a578dffbe2df0e88e9.webp</url>
<title>Caredx Inc</title>
<link>https://6ix.com/company/caredx-inc</link>
</image>
<item>
<title>CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-announces-agreement-to-acquire-naveris-a-leader-in-viral-mediated-cancer-mrd-surveillance-testing</guid>
<pubDate>Tue, 28 Apr 2026 20:05:00 GMT</pubDate>
<description>BRISBANE, Calif., April 28, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial stage precision oncology diagnostics company with a highly differentiated and Medicare-reimbursed, blood‑based monitori</description>
</item>
<item>
<title>CareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation’s 46th Annual Meeting</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-announces-presentation-of-more-than-50-abstracts-including-16-oral-presentations-at-the-international-society-for-heart-and-lung-transplantations-46th-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-announces-presentation-of-more-than-50-abstracts-including-16-oral-presentations-at-the-international-society-for-heart-and-lung-transplantations-46th-annual-meeting</guid>
<pubDate>Tue, 21 Apr 2026 04:00:00 GMT</pubDate>
<description>Breadth of Data Demonstrates the Important Role of Precision Medicine Testing in Post-Transplant Monitoring and Decision Making New SHORE Data Highlights</description>
</item>
<item>
<title>CareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-introduces-alloseq-nano-at-efi-2026-expanding-hla-typing-portfolio-with-long-read-sequencing</guid>
<pubDate>Mon, 20 Apr 2026 11:05:00 GMT</pubDate>
<description>BRISBANE, Calif., April 20, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO blood type genotyping solution, at the European Federation for Immunogenetics (EFI) Conference 2026.</description>
</item>
<item>
<title>CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-announces-agreement-to-divest-lab-products-business-to-eurobio-scientific-for-dollar170-million-and-announces-first-quarter-preliminary-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-announces-agreement-to-divest-lab-products-business-to-eurobio-scientific-for-dollar170-million-and-announces-first-quarter-preliminary-financial-results</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>Transaction Expected to Sharpen CareDx’s Focus on Core Precision Medicine Testing Services and Patient and Digital Solutions, Improve Financial Flexibility,</description>
</item>
<item>
<title>CareDx to Report First Quarter 2026 Financial Results on April 28, 2026</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-to-report-first-quarter-2026-financial-results-on-april-28-2026</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-to-report-first-quarter-2026-financial-results-on-april-28-2026</guid>
<pubDate>Tue, 14 Apr 2026 20:01:00 GMT</pubDate>
<description>BRISBANE, Calif., April 14, 2026--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, April 28, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m.</description>
</item>
<item>
<title>CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx’s Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-announces-vantxtm-an-aipowered-clinical-data-and-analytics-platform-built-on-caredxs-proprietary-large-scale-longitudinal-solid-organ-transplant-datasets-31</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-announces-vantxtm-an-aipowered-clinical-data-and-analytics-platform-built-on-caredxs-proprietary-large-scale-longitudinal-solid-organ-transplant-datasets-31</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>First-of-its-kind, cloud-native AI platform for transplant program cohort analysis, clinical research, and real-world evidence generation announced at the</description>
</item>
<item>
<title>CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-announces-appointment-of-keith-kennedy-as-chief-operating-officer-and-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-announces-appointment-of-keith-kennedy-as-chief-operating-officer-and-chief-financial-officer</guid>
<pubDate>Tue, 24 Feb 2026 22:15:00 GMT</pubDate>
<description>BRISBANE, Calif., February 24, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company’s Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company’s finance organization effective</description>
</item>
<item>
<title>CareDx Announces Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-announces-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-announces-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>Full Year 2025 Total Revenue of $380 Million Increased 14% Year-Over-Year Expects Full Year 2026 Revenue of $420 Million to $444 Million BRISBANE,</description>
</item>
<item>
<title>CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-to-participate-in-the-raymond-james-47th-annual-institutional-investors-conference</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-to-participate-in-the-raymond-james-47th-annual-institutional-investors-conference</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery,</description>
</item>
<item>
<title>CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-announces-clinical-validation-results-120500166</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-announces-clinical-validation-results-120500166</guid>
<pubDate>Thu, 12 Feb 2026 12:05:00 GMT</pubDate>
<description>BRISBANE, Calif., February 12, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced pivotal clinical validation results of AlloHeme™, a non-invasive, next‑generation sequencing (NGS)–based, and artificial intelligence (AI)-powered monitoring test designed to predict relapse i</description>
</item>
<item>
<title>CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-report-fourth-quarter-full-210100466</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-report-fourth-quarter-full-210100466</guid>
<pubDate>Tue, 10 Feb 2026 21:01:00 GMT</pubDate>
<description>BRISBANE, Calif., February 10, 2026--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The Company will host a webcast and conference call that day at 1:3</description>
</item>
<item>
<title>CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-present-alloheme-pivotal-clinical-120500023</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-present-alloheme-pivotal-clinical-120500023</guid>
<pubDate>Tue, 03 Feb 2026 12:05:00 GMT</pubDate>
<description>BRISBANE, Calif., February 03, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, hel</description>
</item>
<item>
<title>CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-participate-btig-13th-annual-210500129</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-participate-btig-13th-annual-210500129</guid>
<pubDate>Tue, 27 Jan 2026 21:05:00 GMT</pubDate>
<description>BRISBANE, Calif., January 27, 2026--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ —, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on Tuesday, February 10, 2026.</description>
</item>
<item>
<title>CareDx to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference </title>
<link>https://6ix.com/company/caredx-inc/news/caredx-participate-btig-13th-annual-medtech-digital-health-life-science-diagnostic</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-participate-btig-13th-annual-medtech-digital-health-life-science-diagnostic</guid>
<pubDate>Tue, 27 Jan 2026 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ —, a leading precision medicine company focused on the discovery,</description>
</item>
<item>
<title>CareDx Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-announces-preliminary-fourth-quarter-120500907</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-announces-preliminary-fourth-quarter-120500907</guid>
<pubDate>Mon, 12 Jan 2026 12:05:00 GMT</pubDate>
<description>BRISBANE, Calif., January 12, 2026--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported preliminary, unaudited financial results for the fourth quarter and full year 2025.</description>
</item>
<item>
<title>CareDx and 10x Genomics to Launch ImmuneScape™ Program – A Multiomics Research Platform to Decode Transplant Rejection and Drug Response</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-10x-genomics-launch-immunescape-120500770</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-10x-genomics-launch-immunescape-120500770</guid>
<pubDate>Wed, 07 Jan 2026 12:05:00 GMT</pubDate>
<description>BRISBANE, Calif., January 07, 2026--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape™, a multiomics research initiative designed by CareDx to eluci</description>
</item>
<item>
<title>CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12-26</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-12-26</guid>
<pubDate>Fri, 26 Dec 2025 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery,</description>
</item>
<item>
<title>CareDx Provides Notice of Proposed Derivative Settlement</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-provides-notice-proposed-derivative-220000792</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-provides-notice-proposed-derivative-220000792</guid>
<pubDate>Thu, 18 Dec 2025 22:00:00 GMT</pubDate>
<description>BRISBANE, Calif., December 18, 2025--CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing.</description>
</item>
<item>
<title>SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation</title>
<link>https://6ix.com/company/caredx-inc/news/shore-study-demonstrates-heartcares-prognostic-value-heart-transplant-recipients</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/shore-study-demonstrates-heartcares-prognostic-value-heart-transplant-recipients</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>Third SHORE Publication Highlights HeartCare’s Role in Risk Stratification and Personalized Post-Transplant Care SOUTH SAN FRANCISCO, Calif.--(BUSINESS</description>
</item>
<item>
<title>CareDx to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/caredx-inc/news/caredx-participate-upcoming-investor-conferences-2025-11-10</link>
<guid isPermaLink="true">https://6ix.com/company/caredx-inc/news/caredx-participate-upcoming-investor-conferences-2025-11-10</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery,</description>
</item>
</channel>
</rss>